Akorn (AKRX) : During the past 4 weeks, traders have been relatively bearish on Akorn (AKRX), hence the stock is down -2.45% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.99% relative to the S&P 500. The 4-week change in the price of the stock is -1.44% and the stock has fallen -0.93% in the past 1 week.
The stock has recorded a 20-day Moving Average of 4.32% and the 50-Day Moving Average is 0.08%. Akorn (NASDAQ:AKRX): stock turned positive on Friday. Though the stock opened at $30.45, the bulls momentum made the stock top out at $30.82 level for the day. The stock recorded a low of $30.09 and closed the trading day at $30.73, in the green by 0.62%. The total traded volume for the day was 1,692,056. The stock had closed at $30.54 in the previous days trading.
The company Insiders own 30.1% of Akorn shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -1.73% . Institutional Investors own 81.84% of Akorn shares. During last six month period, the net percent change held by insiders has seen a change of -1.73%. Also, Deutsche Bank downgrades their rating on the shares of Akorn (NASDAQ:AKRX). The current rating of the shares is Hold. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on August 5, 2016.
Akorn Inc. (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company operates in two segments: Prescription Pharmaceuticals, which is engaged in the sale of branded and generic prescription pharmaceuticals, and Consumer Health, which is engaged in the sale of branded and private label consumer and animal health products. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York, and Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, and an additional warehousing facility in Amityville, New York.